[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2002241736A1 - Method for preventing or treating pain by administering an endothelin antagonist - Google Patents

Method for preventing or treating pain by administering an endothelin antagonist

Info

Publication number
AU2002241736A1
AU2002241736A1 AU2002241736A AU4173602A AU2002241736A1 AU 2002241736 A1 AU2002241736 A1 AU 2002241736A1 AU 2002241736 A AU2002241736 A AU 2002241736A AU 4173602 A AU4173602 A AU 4173602A AU 2002241736 A1 AU2002241736 A1 AU 2002241736A1
Authority
AU
Australia
Prior art keywords
administering
preventing
treating pain
endothelin antagonist
endothelin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002241736A
Inventor
David E. Lebwohl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2002241736A1 publication Critical patent/AU2002241736A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002241736A 2000-12-21 2001-12-19 Method for preventing or treating pain by administering an endothelin antagonist Abandoned AU2002241736A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25784000P 2000-12-21 2000-12-21
US60/257,840 2000-12-21
PCT/US2001/050781 WO2002049630A2 (en) 2000-12-21 2001-12-19 Method for preventing or treating pain by administering an endothelin antagonist

Publications (1)

Publication Number Publication Date
AU2002241736A1 true AU2002241736A1 (en) 2002-07-01

Family

ID=22977974

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002241736A Abandoned AU2002241736A1 (en) 2000-12-21 2001-12-19 Method for preventing or treating pain by administering an endothelin antagonist

Country Status (3)

Country Link
US (1) US6573285B2 (en)
AU (1) AU2002241736A1 (en)
WO (1) WO2002049630A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
EP2060259B1 (en) 2001-11-01 2010-01-20 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US7973064B2 (en) * 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US7351692B2 (en) * 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
GB0219660D0 (en) * 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
AU2003270446A1 (en) * 2002-09-25 2004-04-19 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin
EP1556073B1 (en) * 2002-10-24 2016-01-06 The Board Of Trustees Of The University Of Illinois Method and composition for preventing and treating solid tumors
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
US8217010B2 (en) 2002-10-24 2012-07-10 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
US20070032422A1 (en) * 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
DE602005025755D1 (en) 2004-06-04 2011-02-17 Teva Pharma IRBESARTAN PHARMACEUTICAL COMPOSITION CONTAINING
US20060111345A1 (en) * 2004-11-23 2006-05-25 Transform Pharmaceuticals, Inc. Pharmaceutical compositions comprising a selective COX-2 inhibitor and a diuretic
CN101384255A (en) * 2006-02-09 2009-03-11 癌症治疗公司 Bladder cancer treatment using e09 and propanediol
CN101534852B (en) 2006-08-31 2013-02-13 光谱医药公司 Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists
US20100022574A1 (en) * 2008-07-28 2010-01-28 EndogenX, Inc. Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist
EP2424529B1 (en) 2009-04-30 2016-12-28 Midwestern University Novel therapeutic treatments using centhaquin
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
CN105682741A (en) 2013-07-08 2016-06-15 美国中西部大学 Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
KR100517210B1 (en) 1994-12-12 2006-06-07 오메로스 코포레이션 Infusion solution for pain, inflammation and spasm
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6673832B1 (en) * 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
JP2003535061A (en) 2000-05-31 2003-11-25 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Conjugates of endothelin receptor antagonists and antiepileptic compounds or analgesics with pain-relieving properties

Also Published As

Publication number Publication date
WO2002049630A2 (en) 2002-06-27
US20020082285A1 (en) 2002-06-27
WO2002049630A3 (en) 2003-05-08
US6573285B2 (en) 2003-06-03

Similar Documents

Publication Publication Date Title
AU2002241736A1 (en) Method for preventing or treating pain by administering an endothelin antagonist
AU2002215125A1 (en) Well treatment method
AUPQ867900A0 (en) Medical injector system
AU2001283518A1 (en) Method for controlling the pain from injections or minor surgical procedures andapparatus for use therewith
AU2002223827A1 (en) Well treatment
ZA200109906B (en) Method for treating chronic pain using MEK inhibitors.
AU2001231104A1 (en) Methods for treating diabetes
AU2001238369A1 (en) Method for treating thyroid disorders
AU2002232919A1 (en) Method for treating fibrotic diseases or other indications
ZA200109903B (en) Method for treating chronic pain using MEK inhibitors.
AU2001257342A1 (en) Treatment well tiltmeter system
AU2001255522A1 (en) Mri-resistant implantable device
EP1353676A4 (en) Method for treating fibrotic diseases or other indications
AU2001288458A1 (en) Methods for processing animal tissues
AU2003259249A1 (en) Pyridazinylpiperazine derivatives for treating pain
AU2001253567A1 (en) System and method for projecting market penetration
AU2001227966A1 (en) Methods for treating tumors
AU2001273413A1 (en) Method for treating cancer using an interleukin- 4 antagonist
AU2001255602A1 (en) Methods for treating bone tumors
AU2002210462A1 (en) Transdermal therapeutic system for treating restless-legs-syndrome
AU2002210463A1 (en) Transdermal therapeutic system
AUPQ533700A0 (en) Soil treatment method
AU2002336405A1 (en) Methods for treating deodorizer distillate
AU2001251083A1 (en) Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists
AU2001286983A1 (en) Method of treatment